Skip to main content
    1. Congress Materials

    • European Alliance of Associations for Rheumatology (EULAR), 2026

    Filter
    Close
    Filter
    ⁨⁨⁨⁨Keyword (eg, author, condition)
    Content type:
    Clear filters
    Dapirolizumab pegol treatment and improvement in laboratory markers of disease activity in patients with systemic lupus erythematosus: 48-week results from a phase 3 trial
    Thomas Dörner, David S. Pisetsky, Andrea Fava, et al.
    Poster
    Glucocorticoid-sparing maintenance of disease control in patients with systemic lupus erythematosus: 48-week results from a phase 3 trial of dapirolizumab pegol
    Eric F. Morand, George Bertsias, Lucy M. Carter, et al.
    Poster
    Rheumatoid Factors (RFs) Do Not Bind Fc-Free Certolizumab Pegol, but Do Bind to Fc-Containing Biological DMARDs, Leading to Immune Complex Formation which Induces Cytokine Release from Peripheral Blood Mononuclear Cells (PBMC) In Vitro
    Susanna R. Bidgood, Sophie Hopkin, Jacqueline O’Neill, et al.
    Poster
    Bimekizumab Long-Term Incidence of Psoriatic Arthritis Symptoms and Psoriatic Arthritis Adverse Events in Patients with Psoriasis and Risk Factors for Disease Progression
    Joseph F. Merola, Andreas Pinter, Keiichi Yamanaka, et al.
    Poster
    Bimekizumab Treatment for Patients with Psoriatic Arthritis in Five European Countries: Physician-Reported Outcomes from a Global Real-World Study
    Fabian Proft, Nathalie Quiles-Tsimaratos, Bruce Kirkham, et al.
    Poster
    Bimekizumab Treatment Resulted in Rapid Response That Was Associated with Clinically Important Improvements in Patient-Reported Outcomes up to 3 Years in Patients with Psoriatic Arthritis
    Laure Gossec, Dafna D. Gladman, M. Elaine Husni, et al.
    Poster
    Bimekizumab Inhibited Radiographic Progression Regardless of Baseline Characteristics in bDMARD-Naïve Patients with Active Psoriatic Arthritis: 3-Year Results from a Phase 3 Study and Its Open-Label Extension
    Philipp Sewerin, Laura C. Coates, Philip J. Mease, et al.
    Poster
    Bimekizumab Time to Meaningful Improvements in Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
    Alen Zabotti, Laura C. Coates, Alice B. Gottlieb, et al.
    Poster
    Bimekizumab-Treated Patients with Axial Spondyloarthritis or Psoriatic Arthritis Report Low Long-Term Uveitis Rates: Updated 3-Year Results from Pooled Phase 2b and Phase 3 Studies
    Martin Rudwaleit, Irene E. van der Horst-Bruinsma, Floris A. van Gaalen, et al.
    Poster
    Bimekizumab was Efficacious in Patients with Axial Spondyloarthritis Regardless of Age, BMI, CRP or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
    Marina Magrey, Helena Marzo-Ortega, Yuho Kadono, et al.
    Poster
    Bimekizumab-Treated Patients with Axial Spondyloarthritis Maintained Stringent Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
    Fabian Proft, Sergio Schwartzman, Alexander Marten, et al.
    Poster
    Impact of Bimekizumab on MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Non-Radiographic Axial Spondyloarthritis: 2-Year Results from a Phase 3 Study and its Open-Label Extension
    Walter P. Maksymowych, Sofia Ramiro, Denis Poddubnyy, et al.
    Poster
    Validation of a Disease Activity Index for Psoriatic Arthritis Based on 44 Joints (DAPSA44) Using Data from Phase 3 Clinical Trials of Bimekizumab in Psoriatic Arthritis
    Sofia Ramiro, Dafne Capelusnik, Clementina López-Medina, et al.
    Poster